Zafarullah, Marwa
Tang, Hiu-Tung
Durbin-Johnson, Blythe
Fourie, Emily
Hessl, David
Rivera, Susan M.
Tassone, Flora
Article History
Received: 29 December 2019
Accepted: 18 May 2020
First Online: 6 July 2020
Competing interests
: Dr. Flora Tassone received funding from Zynerba and Azrieli Foundation for carrying out studies in Fragile X Syndrome. Dr. David Hessl received the funding from Zynerba and Ovid Therapeutics regarding fragile X syndrome clinical trials. The other authors authors declare no competing interests.